Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed Multiple Myeloma (NDMM)”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Study completedNCT02891811
What this trial is testing

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Who this might be right for
Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie 124
Testing effectiveness (Phase 2)Looking for participantsNCT06974786
What this trial is testing

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT06679101
What this trial is testing

Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline 520
Early research (Phase 1)Study completedNCT04196491
What this trial is testing

Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 13
Testing effectiveness (Phase 2)Ended earlyNCT02720510
What this trial is testing

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)WithdrawnNCT04258683
What this trial is testing

Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group
Testing effectiveness (Phase 2)Looking for participantsNCT06103838
What this trial is testing

18F-Fluciclovine PET/CT in Multiple Myeloma

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Looking for participantsNCT05828511
What this trial is testing

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 149
Large-scale testing (Phase 3)Looking for participantsNCT06879379
What this trial is testing

KPD Consolidation After ASCT in NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital 202
Very early researchUnknownNCT05840107
What this trial is testing

Study of FasT CAR-T GC012F Injection NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 18
Testing effectiveness (Phase 2)UnknownNCT00378755
What this trial is testing

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Who this might be right for
Multiple Myeloma
Korean Multiple Myeloma Working Party 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT04052880
What this trial is testing

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Who this might be right for
Newly Diagnosed Multiple Myeloma
Larysa Sanchez 17
Testing effectiveness (Phase 2)Study completedNCT02046070
What this trial is testing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 148
Not applicableLooking for participantsNCT06099912
What this trial is testing

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

Who this might be right for
Multiple MyelomaFrailty
FengYan Jin 131
Large-scale testing (Phase 3)Study completedNCT02112175
What this trial is testing

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Who this might be right for
Multiple Myeloma
Celgene 46
Large-scale testing (Phase 3)Looking for participantsNCT06918002
What this trial is testing

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome 824
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Large-scale testing (Phase 3)Looking for participantsNCT05827016
What this trial is testing

Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 1,216
Load More Results